Everest Medicines Ltd
01952
Company Profile
Business description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
Contact
AIA Financial Center, 866 East Changzhi Road
17th Floor
Hongkou District
Shanghai200082
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
812
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,961.50 | 44.10 | -0.49% |
| CAC 40 | 8,385.49 | 44.78 | 0.54% |
| DAX 40 | 24,740.36 | 153.22 | -0.62% |
| Dow JONES (US) | 51,848.90 | 182.06 | 0.35% |
| FTSE 100 | 10,461.63 | 32.78 | 0.31% |
| HKSE | 23,090.27 | 321.91 | -1.37% |
| NASDAQ | 25,476.64 | 110.40 | -0.43% |
| Nikkei 225 | 72,080.43 | 2,905.46 | 4.20% |
| NZX 50 Index | 13,493.31 | 92.65 | 0.69% |
| S&P 500 | 7,358.22 | 7.24 | -0.10% |
| S&P/ASX 200 | 8,760.30 | 40.30 | -0.46% |
| SSE Composite Index | 4,125.76 | 14.94 | 0.36% |